Sera Prognostics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 57
- Market Cap
- -
- Introduction
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.
Sera Prognostics to Present at TD Cowen Conference and Report Q1 2025 Results in May
• Sera Prognostics, focused on maternal and neonatal health through pregnancy biomarker testing, will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, with CEO Zhenya Lindgardt providing company updates.
• The company will report its first quarter fiscal year 2025 financial results on May 7, 2025, followed by a conference call to discuss operational highlights and key developments.
• Sera's flagship PreTRM® Test provides individualized risk assessment for spontaneous preterm birth during weeks 18-20 of pregnancy, addressing a significant health concern that affects more than one in ten U.S. infants annually.
© Copyright 2025. All Rights Reserved by MedPath